Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding by Schott, H et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Synthesis and in vitro activities of new anticancer duplex drugs
linking 2'-deoxy-5-fluorouridine (5-FdU) with
3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding
Schott, H; Schott, S; Schwendener, R
Schott, H; Schott, S; Schwendener, R (2009). Synthesis and in vitro activities of new anticancer duplex drugs
linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Bioorganic &amp; Medicinal Chemistry, 17(19):6824-6831.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Bioorganic &amp; Medicinal Chemistry 2009, 17(19):6824-6831.
Schott, H; Schott, S; Schwendener, R (2009). Synthesis and in vitro activities of new anticancer duplex drugs
linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Bioorganic &amp; Medicinal Chemistry, 17(19):6824-6831.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Bioorganic &amp; Medicinal Chemistry 2009, 17(19):6824-6831.
Synthesis and in vitro activities of new anticancer duplex drugs
linking 2'-deoxy-5-fluorouridine (5-FdU) with
3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding
Abstract
Two isomeric cytostatic duplex drugs 2'-deoxy-5-fluorouridylyl-(3'-->5')-3'-C-ethynylcytidine
[5-FdU(3'-->5')ECyd] and 2'-deoxy-5-fluorouridylyl-(5'-->5')-3'-C-ethynylcytidine
[5-FdU(5'-->5')ECyd] were designed and synthesized at gram scale according to the
hydrogenphosphonate method in an overall yield of about 40%. The in vitro evaluation of the anticancer
effects indicated highly varying sensibilities of the panel of 60 tested tumor cell lines against the duplex
drugs. 5-FdU(3'-->5')ECyd had a 50% growth inhibition (IC(50) < or = 10(-8) M) in 44/58 cell lines.
However, only 25/53 of those cell lines showed corresponding IC(50) values when the isomeric
5-FdU(5'-->5')ECyd was tested. Total growth inhibition was achieved using micromolar concentrations
of the duplex drugs. The 5-FdU residue of the duplex drug can cause very different effects like additive,
synergistic, antagonistic as well as sequence-depending activities, which drastically changed efficiency
as well as specificity of the anticancer activities of the duplex drugs, in comparison to those of the
monomeric drugs.
20.10.2009 09:38 
1 
 
Synthesis and in vitro activities of new anticancer duplex drugs linking 2´-1 
deoxy-5-fluorouridine (5-FdU) with 3´-C-ethynylcytidine (ECyd) via a 2 
phosphodiester bonding 3 
 4 
Herbert Schott
1*
, Sarah Schott
2
, Reto A. Schwendener
3 
5 
 
6 
1
Institute for Organic Chemistry, University Tuebingen, Auf der Morgenstelle 7 
18, D-72076 Tuebingen, Germany, FAX: +49 7071 65782, herbert.schott@uni-8 
tuebingen.de 9 
2
Department of Gynecology and Obstetrics, University of Heidelberg Medical 10 
School, D-69120 Heidelberg, Germany 11 
 
3
Institute of Molecular Cancer Research, University of Zuerich, CH-8057 12 
Zuerich, Switzerland 13 
 14 
Key words: 2´-Deoxy-5-fluorouridine (5-FdU), 3´-C-Ethynylcytidine (ECyd), 15 
Antimetabolites, Cytostatic duplex drugs, Hydrogenphosphonate method 16 
17 
20.10.2009 09:38 
2 
 
ABSTRACT 18 
  Two isomeric cytostatic duplex drugs 2´-deoxy-5-fluorouridylyl-19 
(3´5´)-3´-C-ethynylcytidine [5-FdU(3´5´)ECyd] and 2´-deoxy-5-20 
fluorouridylyl-(5´5´)-3´-C-ethynylcytidine [5-FdU(5´5´)ECyd] were 21 
designed and synthesized at gram scale according to the hydrogenphosphonate 22 
method in an overall yield of about 40 %.  The in vitro evaluation of the 23 
anticancer effects indicated highly varying sensibilities of the panel of 60 tested 24 
tumor cell lines against the duplex drugs. 5-FdU(3´5´)ECyd had a 50 % 25 
growth inhibition (IC50 ≤ 10
-8
 M)  in 44/58 cell lines . However, only 25/53 of 26 
those cell lines showed corresponding IC50 values when the isomeric 5-27 
FdU(5´5´)ECyd was tested. Total growth inhibition was achieved using 28 
micromolar concentrations of the duplex drugs. The 5-FdU residue of the duplex 29 
drug can cause very different effects like additive, synergistic, antagonistic as 30 
well as sequence-depending activities, which drastically changed efficiency as 31 
well as specificity of the anticancer activities of the duplex drugs, in comparison 32 
to those of the monomeric drugs. 33 
34 
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1. Introduction  35 
It is known that antitumor chemotherapy is unsuccessful if resistance 36 
against the administered cytostatic drug occurs. Drug monotherapy, using only 37 
one anticancer compound, often leads to drug resistance. The combination 38 
therapy as an alternative, which is based on a simultaneous or sequential 39 
application of various anticancer drugs, can optimize the therapeutic success and 40 
may prevent resistance. However, combination therapy schedules are often 41 
complex and exhausting for the patients. Another promising but not yet well-42 
evaluated possibility of anticancer combination therapy consists in the chemical 43 
linkage of two different, clinically well-characterized cytostatic drugs into one 44 
molecule, a so called duplex drug. After application of a duplex drug as a 45 
monotherapy the molecule should be degraded into a mixture of several 46 
metabolites each possessing different cytostatic profiles with additive or 47 
synergistic properties. This concept could exploit the advantage of a 48 
combination therapy without additional burden for patients. Cytostatic drugs are 49 
suitable for the design of duplex drugs provided that they vary considerably in 50 
their anticancer mechanisms in order to cause additive or synergistic antitumor 51 
activities and, optimally, a simultaneous reduction of side effects. The chemical 52 
coupling of two single compounds to a new duplex drug must go along with a 53 
justifiable synthetic effort. Furthermore, the molecular structure of the created 54 
duplex drug should allow an in vivo metabolism resulting in multiple active 55 
compounds. Nucleoside analogues 
1-3
 have become a major class of successful 56 
antimetabolites in cancer therapy over many years and fulfill important 57 
preconditions for the preparation of duplex drugs. Two different nucleoside 58 
analogues can be coupled via a natural phosphodiester bonding resulting in 59 
heterodinucleoside phosphate analogues that can easily be cleaved in vivo by 60 
phosphodiesterases into the parent nucleosides. 61 
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Heterodinucleoside phosphates linking 2´-deoxy-5-fluorouridine (5-FdU) 62 
with thioinosine were among the first dimers that inhibited effectively both 6-63 
mercaptopurine sensitive as well as resistant cancer cells in vitro 
4
. However, the 64 
potential of such dimers as possible duplex drugs has not yet been recognized. 65 
The direct coupling of 5-FdU with the lipophilic 2´-deoxy-5-fluoro-N
4
-66 
octadecylcytidine resulted in an amphiphilic heterodinucleoside phosphate 67 
analogue. In in vitro clonogenic growth assays using the human pancreatic 68 
adenocarcinoma cell line MIAPaCa 2, this duplex drug was significantly more 69 
cytotoxic than 5-FdU 
5
. The antitumor potential of the duplex drug evaluated in 70 
p53-mutated and androgen-independent DU-145 human prostate tumor cells 71 
showed a 100% eradication of tumor cells whereas 10 % of cells were resistant 72 
to 5-FdU 
6
. In PC-3 cells the duplex drug exerted stronger cytotoxicity and 73 
induced more S-phase arrest and apoptosis than 5-FdU 
7
. The direct linkage of  74 
arabinofuranosylcytosine (araC) with N
4
-octadecyl-1-ß-D-arabino-75 
furanoylcytosine, a lipophilic derivative of the antitumor drug araC resulted in a 76 
potent duplex drug
8
. An amphiphilic duplex drug can also be stably incorporated 77 
in liposomes. This offers a new opportunity for a targeted anticancer 78 
combination therapy that has been proven in mouse models
9
. The indirect 79 
linkage of 5-FdU and ara-C via a phospholipid backbone resulted in an 80 
amphiphilic duplex drug that might be an additional option for the treatment of 81 
5-FdU sensitive and resistant colon cancer, human lymphoma and hematological 82 
malignancies 
10-12
. 83 
A new derivative of cytidine, 3´-C-ethynylcytidine (ECyd), which is 84 
meanwhile evaluated in clinical studies 
13
, is highly active and suitable for the 85 
synthesis of cytostatic duplex drugs. Because the antitumor mechanism of ECyd 86 
differs from that of 5-FdU it can be expected that the synthesis of dinucleoside 87 
phosphates linking ECyd and 5-FdU, which is described here, will result in a 88 
new duplex drugs with a broad spectrum of antitumor activity based on additive 89 
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or synergistic effects of 5-FdU and ECyd metabolites arising from enzymatic 90 
degradation of the duplex drug. As a proof of principal to this assumption two 91 
isomeric duplex drugs were synthesized by combining 5-FdU and ECyd either 92 
via a 3´5´or a 5´5´phosphodiester linkage to evaluate the  influence of  the 93 
direction of the phosphodiester on the antitumor activity of the dinucleoside 94 
phosphate. 95 
2. Results and Discussion 96 
2.1. Chemistry 97 
The synthesis of the two isomeric duplex drugs summarized in Fig. 1 was 98 
performed according to the phosphonate method. Partially protected ECyd was 99 
used as the 5´-hydroxyl compound 5 whereas two derivatives of 5-FdU were 100 
used as 5´- or 3´-phosphonate compounds 3, 4. According to this concept 101 
dinucleoside phosphates can be synthesized with ECyd at the 3´-and 5-FdU at 102 
the 5´-terminal. The rationale for this synthesis concept is that the necessary 5´-103 
hydroxyl compound of the partially protected ECyd derivative N
4
-benzoyl-2´-O-104 
(tert-butyl-dimethylsilyl)-3´-C-(trimethylsilylethynyl)cytidine 5 occurs as an 105 
intermediate product of the published six step synthesis of ECyd, which used 106 
cytidine as starting material 
14
.  According to the alternative multistep synthesis 107 
of ECyd 
13, 15, 16
 which did not use cytidine as starting compound a fully 108 
protected ECyd was obtained as an intermediate compound. The selective 109 
deprotection of the 5´-or 3´-hydroxyl function of these fully protected ECyd 110 
intermediates cannot easily be performed in order to obtain the desired partially 111 
protected hydroxyl compound for the dinucleoside phosphate synthesis. This 112 
alternative ECyd synthesis concept is therefore less applicable for the synthesis 113 
of the duplex drugs. The synthesis of the sequence isomer duplex drugs with 5-114 
FdU as the 3´ and ECyd as the 5´ terminal, which cannot be obtained according 115 
to our proposed synthesis route is expected to be more complicated. The 116 
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postulated selective derivation of one of three hydroxyl groups of ECyd to 117 
obtain a 3´-hydroxyl or 3´-phosphonate compound of ECyd is more difficult as 118 
in the case of 5-FdU, which has only two hydroxyl groups.  119 
The 5-FdU-3´-phosphonate compound 4 can be obtained from 5-FdU in 120 
two steps, whereas the synthesis of the 5-FdU-5´-phosphonate 3 needs a three 121 
step procedure. The additional steps render the synthesis of 5-FdU-122 
(5´5´)ECyd in respect to the preparation of the isomeric compound 5´-123 
FdU(3´5´)ECyd more difficult.  124 
The synthesis of both phosphonate compounds 3, 4 started with 5´-O-(4-125 
monomethoxytrityl)-2´-deoxy-5-fluorouridine (1) which was obtained from 5-126 
FdU according to published procedures
17
. The phosphonylation of the 3´-127 
hydroxyl residue of 1 resulted with 90 % yield in the desired 3´-phosphonate 128 
compound 5´-O-(4-monomethoxytrityl)-2´-deoxy-5-fluorouridine-3´-hydrogen-129 
phosphonate (4). The 5´-phosphonate compound 3 was also obtained from 1 in 130 
two steps. In the first step protection of hydroxyl groups of 1 with benzoyl 131 
residues followed by removing of the 4´-monomethoxytrityl protection from the 132 
5´hydroxyl group resulted in 92 % yield of 3´,4-di-O-benzoyl-2´-deoxy-5-133 
fluorouridine (2) which was phosphonylated at the 5´-hydroxyl group without 134 
further purification at 82 % yield resulting in the desired 5´-phosphonate 135 
compound 3´-4-di-O-benzoyl-2´-deoxy-5-fluorouridine-5´-hydrogen phos-136 
phonate (3). After coupling of the free 5´-hydroxyl group of 5 with the 5´-or 3´-137 
phosphonate compounds 3 or 4 according to the conditions given in Table 1 the 138 
resulted heterodinucleoside phosphonates were subsequently oxidized with 139 
iodine resulting in the protected heterodinucleoside phosphates. It cannot be 140 
excluded that the unprotected free 3´-hydroxyl group of 5 may be involved in 141 
the condensation reaction. In this case undesired side reactions will occur which 142 
reduces the yield of the desired condensation product. The prevalent 143 
20.10.2009 09:38 
7 
 
condensation reaction, however, should be the coupling to the 5´-hydroxyl group 144 
of 5 because this alcohol function has a sterical advantage for the condensation 145 
reaction in respect to the 3´- hydroxyl group of 5.  146 
After chromatographic purification the different protection groups of the 147 
dimers were removed step by step using the following procedures. At first the 148 
acid labile 4-monomethoxytrityl group of the dimer formed by condensation of 149 
4 + 5 was cleaved with acetic acid. Trimethylsilyl- and tert-butyl-dimethylsilyl 150 
protecting groups of both dimers were removed by treatment with 151 
tetrabutylammonium fluoride (TBAF) and the deprotected dinucleoside 152 
phosphate analogues were obtained as tetrabutylammonium salts. The alkali 153 
labile benzoyl residue was finally removed with ammonia. After the 154 
chromatographic purification of the deprotected dinucleoside phosphate 155 
analogues using a preparative reversed phase (RP-18) column and their 156 
lyophilisation both duplex drugs 2´-deoxy -5-fluorouridylyl-(5´5´)-3´-C-157 
ethynylcytidine (6) and the isomeric 2´-deoxy-5-fluorouridylyl-(3´5´)-3-C-158 
ethynylcytidine (7) were obtained at about 40% yield. The low yield may be 159 
partially explained by possible side reactions during the condensation as 160 
discussed above. The quantitative exchange of the tetrabutylammonium cations 161 
cannot be achieved using a cation exchanger (H
+ 
form). The presence of the 162 
tetrabutylammonium cation in both dinucleoside phosphates was detected by 163 
elementary analysis and mass spectrometry. The course of the synthesis and 164 
purification was controlled by thin-layer chromatography (TLC) on silica gel 165 
plates. The chemical structure and the analytical purity of the products were 166 
confirmed by NMR spectra, elementary analysis and high resolution mass 167 
spectra.  168 
 169 
 170 
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2.2. In vitro anticancer activities  171 
The in vitro antitumor activities of the duplex drugs 5-FdU(3´5´)ECyd, 172 
5-FdU(5´5´)ECyd and of the parent monomeric drugs 5-FdU and ECyd were 173 
evaluated in the framework of the anticancer screen program of the National 174 
Cancer Institute (NCI, USA). The NCI anticancer screen consists of 60 human 175 
tumor cell lines. In those 60 cell lines the drugs are tested at a minimum of five 176 
concentrations at 10-fold dilutions. A 48 h drug exposure protocol and a 177 
sulforhodamine B (SRB) protein assay were used to estimate cell viability or 178 
growth
18
. Additional details can be found at http://dtp.nci.nih.gov. The 179 
anticancer activities were obtained from the data screening report including the 180 
data sheet, dose response curves and the mean graphs. Mean graphs facilitated 181 
visual scanning of data for the selection of potential compounds for particular 182 
cell lines or for particular tumor subpanels with respect to a suspected response 183 
parameter. The response parameter GI50 (log10 of molar sample concentration 184 
resulting in 50 % growth inhibition) of 5-FdU and ECyd given in the mean 185 
graphs are listed in Table 2. The average of the GI50 values for all 60 cell lines is 186 
indicated by the mean graphs midpoint. The comparison of the in vitro tumor 187 
cell growth inhibition activity which is based on the mean graphs midpoint of 188 
ECyd [log10GI50 (M) = -7.6] and of 5-FdU [log10GI50 (M) = -6.4] shows that 189 
ECyd was active against all 60 tested tumor cell lines at  high nanomolar 190 
concentrations and that it was in general about 10-times more cytostatic than 5-191 
FdU. In many cases however, the response of ECyd and 5-FdU to the same cell 192 
line significantly differs as follows. More than a 100-fold difference of the GI50-193 
values of ECyd and 5-FdU was observed in 3/9 non small cell lung; 2/8 194 
melanoma; 2/6 ovarian; 3/8 renal; 5/7 colon and 6/8 breast cancer cell lines. 195 
These data demonstrated a pronounced drug specific antitumor activity of ECyd 196 
and 5-FdU against several cancer cell lines, predominantly in colon and breast 197 
tumor cell lines. Corresponding high differences of GI50 values were not 198 
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observed in the 6 leukemias, 6 CNS and 2 prostate tumor cell lines included in 199 
the screen. 200 
The response parameter GI50 was also used to compare the antitumor 201 
activities of ECyd and both isomeric duplex drugs with the observation of the 202 
following differences of growth inhibition. Half of the tested tumor cell lines 203 
had GI50 values of ≤ 10
-8
 M after ECyd treatment. Correspondingly, 44/58 cell 204 
lines produced low GI50 values with 5-FdU(3´5´)ECyd. However, GI50 values 205 
of ≤ 10-8 M were observed only in 25/53 cell lines when the same cell lines were 206 
treated with isomeric 5-FdU(5´5´)ECyd. On the basis of these results it could 207 
be speculated that the antitumor activities of 5-FdU(3´5´)ECyd linking 5-FdU 208 
with ECyd via the natural 3´5 phosphodiester bonding is generally higher in 209 
respect to those of the  5´5´ isomer. This assumption is in agreement with the 210 
published results that 3´5´linked arabinofuranosylcytidine dimers were found 211 
to be more active than 5´5´ linked dimers19. For the evaluation of the 212 
antitumor activities of the duplex drugs the cell growth inhibition was compared 213 
only with that of ECyd because ECyd was 10-fold more active than 5-FdU. For 214 
this comparison the too low and similar GI50 values of ECyd and the duplex 215 
drugs were less suitable. Therefore, instead of the GI50 the response parameter 216 
TGI (log10 of molar sample concentration resulting in 100% growth inhibition) 217 
listed in Table 2 was used to demonstrate the different sensibility of the same 218 
tumor cell lines against ECyd and the duplex drugs. 219 
The mean graphs midpoint of ECyd [log10TGI (M) = -5.56 corresponds to 220 
the values of 5-FdU-(3´5´)ECyd [log10 TGI (M) = -5.28 and of 5-221 
FdU(5´5´)ECyd [log10TGI (M) = -5.39. In respect to the similar TGI mean 222 
graphs midpoint of the three compounds it could be assumed that the cytostatic 223 
potential of ECyd and both duplex drugs would be similar. However, the TGI 224 
values of the drugs obtained after the parallel treatment of the same tumor cell 225 
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line clearly demonstrated that the main part of the 60 tested cell lines showed  226 
significantly different sensibilities against ECyd, 5-FdU(3´5´)ECyd and 5-227 
FdU(5´5´)ECyd because their responses against single cell lines varied in a 228 
broad range. 229 
The following 14 cell lines showed TGI values of ECyd (see Table 2), 230 
which are more than 10-fold lower than those of one or both duplex drugs: 231 
Melanomas (SK-Mel-2); ovarian (OVAR4); colon (SW-620); CNS (SNB-19, 232 
U251); renal (ACHN, TK-10, UO-31); non small lung (NCI-H23, NCI-H322M, 233 
NCI-H460, NCI-H522) and the prostate cancer cell lines (PC-3, DU-145). On 234 
the basis of these TGI values it can be concluded that the equimolar coupling of 235 
5´-FdU with ECyd results in an antagonistic effect, thus reducing the cytostatic 236 
activity of the duplex drug, in respect to that of ECyd..  237 
In contrast to these results the following 9 cell lines were more than 10-238 
times more sensitive to one or both duplex drugs in comparison to ECyd: HL-239 
60, Molt-4 (leukemia); SF-539 (CNS); OVCAR-8 (ovarian); MCF7, NCI/ADR-240 
RES, MDA-MB-231, HS 578T; BT-549 (breast). In these examples the linked 241 
5-FdU acts additively or synergistically when coupled with ECyd. Of the tested 242 
cell lines 27 showed only little to unchanged growth inhibition in comparison to 243 
that of ECyd independently of treatment with 5-FdU(3´5´)ECyd or 5-244 
FdU(5´5´)ECyd.The double screened TGI values of 18 tests of the 60 tested 245 
cell lines could not be evaluated because the values obtained differed more than 246 
100-fold. 247 
Besides the change of the cytostatic activities of ECyd, which was 248 
observed after coupling with 5-FdU it was surprising that the direction of the 249 
phosphodiester linkage sequence in which 5-FdU and ECyd were coupled has a 250 
significant influence on the antitumor activity and specificity of the synthesized 251 
duplex drugs. However, 25 of the tested 60 cell lines demonstrated a marked 252 
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structure-activity relationship against the duplex drugs. The sequence dependent 253 
antitumor activity can be observed from the difference of the TGI values 254 
resulting after parallel treatment of the same cell line with 5-FdU(3´5´)ECyd 255 
and 5-FdU(5´5´)ECyd. One half of these cell lines were more sensitive 256 
against 5-FdU(3´5´)ECyd whereas the other half showed higher growth 257 
inhibition with the isomeric 5-FdU(5´5´)ECyd duplex. The following 7 cell 258 
lines showed a significant high sequence activity relationship expressed by an 259 
about 100-fold difference of the TGI values obtained with the same cell line 260 
after parallel treatment with both duplex drugs: Molt-4, SR (leukemia); HOP-62, 261 
NCI-H23 (non small cell lung cancer); DU-145 (prostate); MCF7; MDA-MB-262 
231(breast). 263 
The results demonstrate that the chemical coupling of 5-FdU and ECyd 264 
caused, depending on the cell lines resulted either in increased, decreased or 265 
unchanged antitumor activities of the corresponding duplex drug compared to 266 
monomeric ECyd. Activity and specificity of the antitumor effects of the duplex 267 
drugs depend on the cytostatic potential of the coupled monomeric drugs as well 268 
as on the structure of the obtained dimer, for example the direction of the 269 
phosphodiester bonding in a dinucleoside phosphate. Thus, the described 270 
transformation of cytostatic antimetabolites to dinucleoside phosphate analogues 271 
represents a valuable alternative to the intensive search for new anticancer 272 
drugs. 273 
2.2.2. Possible reasons of the antitumor activities of the duplex drugs 274 
The rationale for the synthesis of a duplex drug linking 5-FdU and ECyd 275 
is based on the high antitumor potential of both antimetabolites based on 276 
different action mechanisms. The principal mechanism for the cytostatic effect 277 
of 5-FdU is the inhibition of thymidylate synthase (TS)
20
. The inhibition of TS 278 
enzyme activity leads to depletion of deoxythymidine triphosphate which is 279 
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necessary for DNA synthesis. ECyd can contribute to the antitumor activity 280 
through its action mechanisms which are different from those of 5-FdU 
21-25
. 281 
ECyd is phosphorylated by uridine-cytidine kinase to the corresponding 5´-282 
monophosphate and upon further phosphorylation by nucleotide kinase the 283 
cytostatically active triphosphate competitively inhibits RNA synthesis which 284 
ultimately leads to tumor cell apotosis. In ECyd resistant cell lines, cellular 285 
uptake of ECyd and accumulation of ECyd-5´-triphosphate are downregulated 286 
as compared to parental cells. 287 
By coupling ECyd and 5-FdU the resulting duplex drug should be a potent 288 
inhibitor of tumor cell growth by simultaneous inhibition of both DNA and 289 
RNA synthesis. It can be supposed that the intact duplex drugs do not act as 290 
active compounds. However, the several cytostatic metabolites, which can be 291 
formed by enzymatic degradation of the duplex drugs should initiate the 292 
antitumor effects. Because the phosphodiester cleavage can either be initiated at 293 
the 3´- as well as the 5´-terminal, a mixture of different active metabolites can 294 
be expected. The cleavage of 5-FdU(3´5´)ECyd produces an equimolar  295 
mixture of ECyd-5´-monophosphate and 5-FdU if the phosphodiesterase cleaves 296 
at the 3´-terminal. Cleavage at the 5´-terminal results in a mixture of 5-FdU-3´-297 
monophosphate and ECyd. The degradation of the isomeric 5-FdU(5´5´)ECyd 298 
results in a 1:1 molar mixture of 5-FdU-5´-monophosphate and ECyd if 299 
cleavage occurs at the 5-FdU residue. An equimolar  mixture of ECyd-5´-300 
monophosphate and 5-FdU will be formed if cleavage occurs at the ECyd 301 
residue of the duplex drugs. Molar amounts and structure of the formed 302 
metabolites depend on the specificity and activity of the different 303 
phosphodiesterases. However, certain steps of the metabolic pathway can be 304 
favored, if for example the recognition and cleavage of the ECyd will be 305 
hindered by the 3´-C-ethynyl group of the carbohydrate residue, whereas the 306 
unmodified carbohydrate residue of 5-FdU is more accessible to the enzyme.  307 
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The antitumor activity of ECyd depends essentially on its 308 
phosphorylation. The first phosphorylation step from ECyd to ECyd-5´-309 
monophosphate is unnecessary if ECyd-5´-monophosphate is produced by 310 
metabolic action. In this example the nucleotide sequence of the duplex drug 311 
which favors the metabolic pathway resulting in ECyd-5`-monophosphate 312 
instead of ECyd can result in increased antitumor activity of the duplex. Under 313 
this aspect the other sequence isomeric dinucleoside phosphate ECyd(3´5´)5-314 
FdU with ECyd as the 5´- and 5-FdU as the 3´terminal coupling partner is less 315 
favored to be metabolized by phosphodiesterase to ECyd-5´-monophosphate in 316 
comparison to 5-FdU(3´5´)ECyd. This duplex drug was therefore not 317 
synthesized. 318 
In addition to phosphodiesterase cleavage phosphohydrolases can convert 319 
the phosphorylated metabolites to the corresponding nucleosides. The main part 320 
of the duplex drug will be metabolized before reaching the cytoplasm because 321 
the negatively charged phosphodiester renders the dinucleoside phosphate too 322 
hydrophilic to penetrate the lipid rich cell membrane easily 
26
. The extracellular 323 
release of active metabolites may cause a depot effect which does not occur by 324 
application of a mixture of 5-FdU and ECyd. The suspected extracellular 325 
metabolism could be a disadvantage if duplex drugs are synthesized as 326 
hydrophilic heterodinucleoside phosphate analogues. 327 
In case that the metabolism of both isomeric duplex drugs would produce 328 
an identical mixture of active metabolites the observed structure-activity 329 
relationship would be difficult to explain and no difference between the 330 
cytostatic effects of both duplex drugs and of a mixture of 5-FdU and ECyd 331 
could be expected. Thus, it can be speculated that the sequence dependent 332 
metabolic pathways which produce in a time dependent manner different 333 
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amounts and species of cytotoxic metabolites can modulate their antitumor 334 
activity and tumor cell specificity. 335 
The results of the in vitro cytotoxicity test screens provide a preliminary 336 
orientation of expected in vivo antitumor activities. However, a wide variety of 337 
biochemical and physiological processes can drastically influence the patterns of 338 
the antitumor effects in vivo. For example, it has been reported that a duplex 339 
drug tested on murine leukemia cells with the highest cytotoxicity in vitro 340 
exerted the lowest therapeutic effect in vivo
12
. Nevertheless, the excellent in 341 
vitro antitumor activities of the described new duplex drugs justify further 342 
evaluation in in vivo tumor models.  343 
3. Experimental  344 
3.1. General chemistry 345 
3.1.1 Reagents 346 
Pivaloyl chloride, benzoyl chloride, tetrabutyl ammonium fluoride 347 
trihydrate, p-toluenesulfonic acid monohydrate were obtained commercially. 348 
Salicylchlorophosphite 
27
 5’-O-(4-monomethoxytrityl)-2’-deoxy-5-fluorouridine 349 
(1)
17
, N
4
-benzoyl-2’-O-(tert-butyldimethylsilyl)-3’-(trimethylsilyl-ethynyl) 350 
cytidine (5)
14
 were prepared as described. All solvents were of technical grade 351 
and used without further purification unless stated otherwise. Dioxane was dried 352 
with sodium, distilled and stored over 5Å molecular sieve and pyridine was 353 
refluxed over KOH, distilled and stored over 4Å molecular sieve. The TBAF 354 
cleaving solution was obtained by dissolving tetrabutyl ammoniumfluoride 355 
trihydrate (157.8 g) in THF (500 mL). For the oxidation reaction a solution of 356 
iodine (25 g) in THF (500 mL) was used. All reactions were monitored by TLC 357 
on precoated silica gel 60 F254 plates (0.25 mm, Merck) using UV light for 358 
visualization and spray reagents as developing agents
11
. Multi step flash 359 
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chromatography was carried out on self packed silica gel 60 (0.040 – 0.0063 360 
mm, Merck) columns using eluent mixtures prepared by volume ratios. All 361 
reactions were performed at room temperature, if not stated differently. The 362 
concentration of the reaction mixtures, solutions, organic layers and eluted 363 
fractions was done in vacuum at a bath temperature of 40°C. 
1
H- and 
13
C-NMR 364 
spectra were obtained on a Bruker AC 250 spectrometer at 250 MHz and 62.9 365 
MHz, respectively or on a Bruker Avance 400 spectrometer at 400 MHz und 366 
100 MHz, respectively.  DMSO-d6 was used as solvents. Me4Si was used as an 367 
internal standard. 
31
P-NMR spectra were obtained on a Bruker Avance 400 368 
spectrometer at 161 MHz, using H3PO4 as an external standard. Mass spectra 369 
were measured on a Finnigan TSQ 70 or a MAT 95 instrument. For FAB mass-370 
spectra, all compounds were measured in a NBA-or glycerine-matrix. HRMS 371 
were measured on a Bruker Apex II FT-ICR instrument. 372 
 373 
3.2. General chemistry methods. 374 
3.2.1. Condensation procedure using the hydrogenphosphonate method. 375 
The corresponding hydroxyl- and hydrogen phosphonate compounds were 376 
dissolved together in dry pyridine and rigorously dried by repetitive evaporation 377 
and addition of pyridine before the condensation reaction was started by 378 
addition of pivaloyl chloride. After drying and addition of the required amount 379 
of pyridine (see Table. 1.) the solution was cooled to 0°C before pivaloyl 380 
chloride was added under exclusion of moisture. After stirring for 5 min the 381 
reaction mixture was cooled again to 0°C before the reaction was stopped by 382 
addition of water. The obtained phosphonic diester was immediately oxidized by 383 
addition of iodine in THF and H2O. After 1 h stirring excess iodine was reduced 384 
by addition of solid sodium hydrogen sulphite before the reaction mixture was 385 
concentrated to a syrup that was dissolved in CHCl3/MeOH and extracted with 386 
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water. The organic layer was concentrated to a syrup, which was co-evaporated 387 
three times with toluene yielding the crude protected heterodinucleoside 388 
phosphates, which were purified and de-protected as described below. 389 
 390 
3.3. Synthesis of 3’, 4-Di-O-benzoyl-2’-deoxy-5-fluorouridine-5’-hydrogen-391 
phosphonate (3) 392 
To a solution of 5’-O-(4-monomethoxytrityl)-2´-deoxy-5-fluorouridine (1) 393 
(26 g, 50 mmol) in dry pyridine (150 ml) benzoylchloride (56 g, 400 mmol) was 394 
added under cooling. The reaction vessel was sealed airtight and shaken for 8 h 395 
at room tempature before saturated (sadt.) aq. Na2CO3 (130 mL) was added 396 
under cooling. The resulting reaction mixture was concentrated to a syrup which 397 
was diluted with CHCl3 (300 mL) and then extracted with satd. aq. Na2CO3 (130 398 
mL). The CHCl3 layer was concentrated to a syrup which was dissolved in a 399 
mixture of CHCl3/petroleum ether (1/1, 200 mL) followed by chromatography 400 
on a silica gel column using a CHCl3/petroleum ether gradient with increasing 401 
percentage of CHCl3. The fractions containing the desired product were 402 
concentrated to a foam (46 g) which was dissolved in acetone (100 mL) 403 
containing p-toluenesulfonic acid monohydrate (16 g) and stirred for 20 min at 404 
room temperature, before satd. aq. Na2CO3 (50 mL) was added. The resulting 405 
solution was concentrated to a syrup which was dissolved in CHCl3 (500 mL) 406 
and extracted with H2O (100 mL). The organic layer was separated and 407 
chromatographed on a silica gel column using a two step gradient with step 1; 408 
CHCl3/petroleum ether with increasing percentage of CHCl3 and step 2; ether. 409 
The fractions containing the desired product were concentrated, affording crude 410 
3’,4-di-O-benzoyl-2’-deoxy-5-fluorouridine (2) as a colourless foam (21 g, 46 411 
mmol) at 92% yield.  In the following step 2 was dissolved without further 412 
purification in dry pyridine (90 mL) and diluted with dry dioxane (180 mL). To 413 
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this solution dioxane (75 mL) was added in which salicylchlorophosphite (13 g, 414 
64 mmol) was dissolved. After stirring of the reaction mixture at room 415 
temperature for 2 h satd. aq. NaHCO3 (12 mL) was added and the solution was 416 
evaporated to a syrup which was dissolved in CHCl3 (500 mL) and extracted 417 
with a mixture  of H2O/satd. aq. NaCl/MeOH (1/1/2) (3x 100 mL). The 418 
separated CHCl3-phase was concentrated and the resulting syrup dissolved in 419 
CHCl3 (150 mL). By slow addition of the obtained solution to vigorously stirred 420 
ether (1.5 L) the desired 3 precipitated. The isolated and dried precipitate was 421 
then extracted during 70 h with ether. After drying of the remaining precipitate, 422 
3 (20 g, 39 mmol) was obtained at 82% yield as a white powder. TLC 423 
(CHCl3/MeOH 70/30) Rf= 0.46 ; MS (FAB
-
) m/z : 517,1 [M-H]
-
;
 1
H-NMR, 400 424 
MHz, DMSO-d6:  = 2,44-2,75 (m, 2H, H2’), 3,48-3,89 (m, 5H, PH, H2O 425 
(DMSO-d6)), 4,0-4,425 (m, 2H, H5’), 4,34-4,47 (m, 1H, H4’), 5,47-5,64 (m, 1H, 426 
H3’), 6,22-6,4 (m, 1H, H1’), 7,35-8,27 (m, 10H, Haromat.), 8,51 (s 1H, H6), 12,0 (s, 427 
br, 1H, P-OH); 
13
C-NMR, 100 MHz, DMSO-d6: = 36,7 (C2’), 62,8 (C5’), 75,5 428 
(C3’), 83,6 (C1’), 85,4 (C4’), 128,6-147,9 (Caromat.), 155,7 (C6), 156,0 (C5), 165,1 429 
(C=O), 168,0 (C=O); 
31
P-NMR, 161 MHz, DMSO-d6:  = 1,23ppm( -O-PH(O)-430 
OH); Anal. calcd. for C23H20FN2O9P * Na * ½ H2O: C 50.28; H 3.67; N 5.10; 431 
Found: C 50.30; H 4.21; N 5.35. 432 
 433 
3.4. Synthesis of 5’-O-(4-Monomethoxytrityl) -2’-deoxy-5-fluorouridine-3’-434 
hydrogenphosphonate (4). 435 
5’-O-(4-Monomethoxytrityl)-2’-deoxy-5-fluorouridine (1) (20 g, 39 436 
mmol) was dissolved in dry pyridine (50 mL) and the resulting solution diluted 437 
with dry dioxane (90 mL) followed by addition of salicylchlorophosphite (11 g, 438 
54 mmol). After stirring the reaction mixture at room temperature for 1.5 h the 439 
formed precipitate was removed by filtration and washed with cold ether. To the 440 
20.10.2009 09:38 
18 
 
combined filtrate and wash liquid satd. aq. Na2CO3 (50 mL) was added. The 441 
obtained mixture was concentrated to a foam which was then dissolved in a 442 
mixture of CHCl3/MeOH (95/5) and chromatographed on a silica gel column 443 
using a CHCl3/MeOH elution gradient with increasing percentage of MeOH. 444 
After the evaporation of the product containing fractions compound 4 was 445 
obtained as a foam (20 g, 35 mmol) at 90% yield. TLC (CHCl3/MeOH 80/20) 446 
Rf= 0.17; MS (FAB
-
) m/z: 581.2 [M-H]
-
; 603.2[M+Na];
1
H-NMR, 400 MHz, 447 
DMSO-d6:  = 2,20-2,65 (m, 2H, H2’), 3,18-3,43 (m, 2H, H5’), 3,45-3,68 (m, 3H, 448 
NH, PH, POH), 3,73 (s, 4H, OCH3, H2O (DMSO-d6)), 4,21 (m, 1H, H4’), 4,91 449 
(m, 1H, H3’), 6,23 (m, 1H, H1’), 6,79-7,48 (m, 14H, Haromat.), 7,79 (d, 1H, J= 6,2 450 
Hz, H6); 
13
C-NMR, 100 MHz, DMSO-d6:  = 23,4 (C2’), 60,0 (OCH3), 61,6, 451 
(C5’), 68,4 (C3’), 89,9 (C4’), 91,8 (C1’), 128,9 (C6), 132,0.148,9 (Caromat.+ C5), 452 
154,2 (C=O), 163,5 (C=O); 
31
P- NMR, 161 MHz, DMSO-d6:  = 7,3 ppm,  (-O-453 
PH(O)-OH); Anal. calcd for C29H28FN2O8P*2Na*H2O: C 53.96; H 4.53; N 4.34. 454 
Found: C 53.55; H 4.44; N 4.17. 455 
 456 
3.5. Synthesis of 2’-deoxy-5-fluorouridylyl-(5’5’)-3’-C-ethynylcytidine (6). 457 
The syrup obtained after the condensation of 5 with 3 according to the 458 
experimental data of Table 1 was dissolved in CHCl3 and chromatographed on a 459 
silica gel column using a CHCl3/MeOH gradient with increasing percentages of 460 
MeOH. The fractions containing the desired protected heterodinucleoside 461 
phosphate were concentrated to a syrup which changed to a fine solid by 462 
vigorously shaking after addition of ether. To the isolated solid, dissolved in 463 
THF (45 mL) a solution (22 mL) of TBAF in THF was added. The sealed 464 
reaction mixture was stirred for 3 days whereby the trimethylsilyl- and tert.-465 
butyl-dimethylsilyl protecting groups were cleaved. After the concentration of 466 
the reaction mixture 33% aq. ammonia (80 mL) was added to the resulting syrup 467 
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and the sealed solution was stirred for 5 days to cleave the benzoyl protecting 468 
groups. When the reaction mixture was concentrated to about 250 mL, a fine 469 
solid precipitate was removed by centrifugation and the supernatant liquid 470 
concentrated and lyophilizised. The resulting lyophilisate of crude 6 was 471 
dissolved in H2O (60 mL) and chromatographed on a preparative RP-18 column 472 
using a H2O/MeOH gradient with increasing percentage of methanol. The 473 
desired 6 eluted at 15-40% CH3OH. The product containing fractions were 474 
pooled, the pH value adjusted to 5.8 by addition of a cation exchanger  resin 475 
(H
+
), that was removed before the solution was concentrated and lyophilized 476 
yielding 6 as a white  powder (5.8 g, 41.8 %). 477 
HRMS calcd for C20H22FN5O12P [M-H]
-
: 574,09921. found: 574,09907; 
1
H-478 
NMR (DMSO-d6, 250 MHz):  = 11.,8 (br, s, 1H, NH-5FdU), 8,10 (d, J=6,64 479 
Hz, 1H, H6-5FdU), 7,85 (d, J=7,25 Hz, 1H, H6-ECyd), 6,14 (t, J=6,42 Hz, 1H, 480 
H1-5FdU), 5,85 (d, J= 6,19 Hz), 1H, H1-ECyd) 5,81 (d, J= 7,07 Hz, 1H, H5-481 
ECyd), 5,64-5,75 (m, 2H, H2’-OH, H3’-OH-ECyd), 4,29 (m, 1H, H3’-5FdU), 4,08 482 
(m, 1H, H2’-ECyd), 3,83-3,97 (m, 6H, H4’-,H5’-,H5’’-ECyd/5FdU), 3,46 (s, 1H, 483 
CH-ECyd) 3,16 (m, 8H, NCH2-TBA), 2,10 (m, 2H, H2’, H2’’-5FdU) 1,56 (m, 484 
8H, CH2-C2H5-TBA), 1,30 (m, 8H, CH2-CH2-TBA), 0,92 (m, 12H, CH3-TBA); 485 
13
C-NMR (DMSO-d6, 62 MHz):  = 165,3 (C4-ECyd), 158,0 (C4-5FdU), 156,9 486 
(C2-ECyd), 149,1 (C2-5FdU), 142,2 (C6-ECyd), 137,8 (C5-5FdU), 124,6 (C6-487 
5FdU), 94,4 (C5-ECyd), 87,3 (C1’-ECyd), 86,3 (C4’-ECyd), 84,6 (C4’-5FdU), 488 
82,9 (CH-ECyd), 78,7 (C2’-ECyd), 77,3 (C-ECyd), 72,7 (C3’-ECyd), 71,1 489 
(C3’-5FdU), 64,6 (C5’-ECyd, C5’-5FdU), 57,6 ( C1-TBA), 23,1 (C2-TBA), 19,2 490 
(C3-TBA), 13,5 (C4-TBA); Anal. calcd. for C20H22FN5O12P *C16H36N: C 52.93, 491 
H 7.16, N 10.29; found: C 52.58, H 6.86, N 9.56; 31P-NMR, 161 MHz DMSO-492 
d6 :  = -1.5 ppm. 493 
 494 
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3.6. Synthesis of 2’-deoxy-5-fluorouridylyl-(3’5’)-3’-C-ethynylcytidine (7). 495 
The syrup, obtained after condensation of 5 with 4 according to the 496 
experimental data of Table 1 was dissolved in CHCl3 (300 mL) and 497 
chromatographed on a silica gel column using mixtures of CHCl3/MeOH with 498 
increasing percentages of MeOH as the eluent. Fully protected 7 was eluted first, 499 
followed by fractions containing 7 without the monomethoxytrityl protection 500 
group. Fractions containing fully protected as well as partially deprotected   7 501 
were pooled and concentrated to a foam which was dissolved in MeOH (60 mL). 502 
Then 80% aq. acetic acid (60 mL) was added, the reaction mixture stirred for 24 503 
h and then concentrated to a syrup. The syrup changed to a fine solid after 504 
adding ether and vigorous shaking. The solid was isolated by centrifugation, 505 
dissolved in CHCl3 (250 mL) and re-chromatographed on a silica gel column as 506 
described above. After the second chromatographic purification the resulting 507 
solid of the partially protected 7 was dissolved in THF (170 mL), followed by 508 
addition of TBAF (8 mL). The sealed reaction mixture was stirred for 3 days 509 
and concentrated to a syrup. The obtained syrup was treated another 5 days with 510 
33% aq. ammonia (300 mL) and chromatographed on a RP-18 column as 511 
described above for the purification of 6 affording pure 7 (10.6g, 39.3 %).  512 
MS (FAB
-
) m/z: 574.0 [M-H]
-
; 815.3 [M+C16H36N]
-
; 
1
H-NMR (DMSO-d6, 250 513 
MHz): = 11,82 (br, s, 1H, NH-5FdU), 8,20 (d, J=7,1 Hz, 1H, H6-5FdU), 7,92 514 
(d, J=7,5 Hz, 1H, H6-ECyd), 7,83 (d, J=7,5 Hz, 1H, H5-ECyd), 6,09-6,14 (m, 515 
2H, 2xH1’-ECyd/5FdU) 5,69-5,85 (m, 6H, OH/NH-ECyd/5FdU), 4,65 (m, 1H, 516 
H3’-5FdU), 3,87-4,01 (m, 4H, H5’-ECyd/H3’-5FdU), 3,59 (m, 2H, H5’-5FdU), 517 
3,48 (s, 1H, CC-H), 3,16 (m, 8H, N-CH2-TBA), 2,50 (m, 1H, H2’-ECyd), 2,28-518 
2,1 (m, 2H, H2’-5FdU), 1,53 (m, 8H, CH2-TBA), 1,30 (m, 8H, CH2-TBA), 0,92 519 
(t, J=7,4, 12H, CH3-TBA); 
13
C-NMR (DMSO-d6, 62 MHz):  = 165,0 (C4-520 
ECyd), 158,0 (C4-5FdU), 157,29 (C2-ECyd), 149,0 (C2-5FdU), 142,2 (C6-521 
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ECyd), 137,8 (C5-5FdU), 124,6 (C6-5FdU), 94,4 (C5-ECyd), 87,5 (C1’-ECyd), 522 
86,5 (C4’-ECyd), 84,5 (C4’-5FdU), 82,9 (CH-ECyd), 78,7 (C2’-ECyd), 77,4 523 
(C-ECyd), 74,5 (C3’-5FdU), 72,6 (C3’-ECyd), 65,2 (C5’-ECyd), 61,5 (C5’-524 
5FdU) 57,6 ( C1-TBA), 23,1 (C2-TBA), 19,2 (C3-TBA), 13,5 (C4-TBA); 
31 
P-525 
NMR, 161 MHz, DMSO-d6:  = -1.85 ppm; Anal. calcd for 526 
C20H22FN5O12P*C16H36N: C 52.93, H 7.16, N 10.29; found: C: 52.62, H 7.00, N 527 
9.60  528 
 529 
 530 
 531 
532 
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Table 1.  584 
Experimental data for the synthesis according to the hydrogen phosphonate 585 
method yielding the fully protected isomeric heterodinucleoside phosphates of 586 
2’-deoxy-5-fluorouridylyl-(5’5’)-3’-C-ethynylcytidine (6) and of 2’-deoxy-5-587 
fluorouridylyl-(3’5’)-3’-C-ethynylcytidine (7). 588 
Experimental data for the 
condensation 
Obtained protected crude heterodinucleoside 
phosphates 
                       6                                  7 
Hydroxyl compound 
number, (g/mmol) 
 
5, 9.5/ 17 
 
5, 18.4/33 
Phosphonate compound 
number, (g/ mmol) 
+ 
3, 11.0/21.2 
+ 
4, 19.2/33 
Pyridine (mL) 80 100 
Pivaloylchloride (mL/mmol) 13/106 24/195 
H2O (mL) 10 20 
Iodine in THF (mL) + H2O 
(mL) 
80 + 10 160 + 20 
CHCl3/MeOH (9:1) (mL) 200 300 
H2O (mL) 150 250 
 589 
590 
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Table 2 591 
In vitro anticancer activities resulting in 50 % growth inhibition (log10 GI50) of 592 
the monomeric drugs 5-FdU and ECyd and the 100 % growth inhibition (log10 593 
TGI) of the duplex drugs 5-FdU(3´5´)ECyd, 5-FdU(5’5’)ECyd and ECyd 594 
which were screened twofold  on 60 human cancer cell lines (panel /cell line) 595 
and expressed by sample concentration (M). Results of one representative screen 596 
are shown. The lowest GI50 value of ECyd and 5-FdU being more than 100-fold 597 
different in the same cell lines and the lowest TGI values of  ECyd and of the 598 
two duplex drugs being more than 10-fold different in the same cell lines are 599 
shown by bold face. 600 
 601 
Panel/Cell line  Log10 GI 50(M) 
  
Log10 TGI (M) 
 5-FdU ECyd ECyd 5-FdU(3’5’)ECyd 5-FdU(5’5’)ECyd 
Leukemia      
CCRF-CEM -8.2 <-8.0 -5.90 -5.65 -5.76 
HL-60 -6.7 <-8.0 > -4.00 -5.98 a 
K-562 -6.1 < -8.0 >- 4.00 > -4.00 > -4.00 
MOLT-4 -7.4 < -8.0 -4.99 -4.82 -7.91 
RPMI-8226 -6.1 < -8.0 -6.89 a -7.78 
SR -7.9 < -8.0 a -6.85 > -4.00 
Non-small cell 
lung cancer 
     
A549/ATCC -7.9 < -8.0 -4.00 > -4.53 > -4.00 
EKVX -5.0 -7.2 -5.40 -5.20 -5.05 
HOP-62 -7.6 < -8.0 a > -4.00 -6.77 
HOP-92 -6.1 -7.2 -5.36 -5.66 -4.67 
20.10.2009 09:38 
26 
 
NCI-H226 -5.0 -7.8 a -4.89 > -4.00 
NCI-H23 -6.3 -7.5 -6.59 -4.84 -6.92 
NCI-H322M -6.3 -7.7 -5.94 -4.94 a 
NCI-H460 -8.7 < -8.0 -7.00 -4.99 -5.34 
NCI-H522 -5.6 < -8.0 -7.45 -5.94 > -4.00 
Colon cancer      
COLO 205 -5.8 <- 8.0 -6.71 -6.06 -6.02 
HCC-2998 -9.0 < -8.0 -7.40 -6.96 a 
HCT-116 -6.9 <- 8.0 -4.94 >- 4.00 >- 4.00 
HCT-15 -5.7 <- 8.0 > -4.00 -4.82 > -4.00 
HT29 -5.6 < -8.0 a > -4.00 >- 4.00 
KM12 -5.2 < -8.0 -6.06 -5.08 -5.25 
SW-620 -5.0 <- 8.0 -5.89 > -4.00 > -4.00 
CNS cancer      
SF-268 -7.9 -7.8 -5.89 -5.11 -5.54 
SF-295 -7.4 <- 8.0 -6.24 -5.97 -6.06 
SF-539 -8.4 -7.4 -5.17 -6.78 -6.86 
SNB-19 -5.7 -7.2 -5.24 > -4.00 > -4.00 
SNB-75 -6.7 -7.8 a -6.05 a 
U251 -6.9 -7.7 -5.78 >- 4.00 > -4.00 
Melanomas      
LOXI MVI -7.6 <- 8.0 -7.42 -6.46 a 
MALME-3 M -5.1 -7.8 -6.28 -5.89 -6.49 
M14 -6.8 -7.4 -5.57 -6.54 -6.14 
SK-MEL-2 -5.0 -7.9 -6.60 -6.37 -5.24 
SK-MEL-28 -5.7 -7.3 -5.76 -5.85 -6.42 
20.10.2009 09:38 
27 
 
SK-MRL-5 -6.7 -8.0 -6.46 -6.80 -7.39 
UACC-257 -5.5 -7.1 -5.27 -5.66 -5.27 
UACC-62 -7.4 -7.5 -6.51 -5.89 -6.53 
Ovarian cancers      
IGROV1 -5.6 -7.9 -4.84 -4.89 >-4.00 
OVCAR-3 -5.6 -7.1 -5.37 -5.54 -6.13 
OVCAR-4 -5.0 -6.8 -5.81 -5.70 > -4.00 
OVCAR-5 -5.2 -7.3 a -4.95 -4.46 
OVCAR-8 -6.9 <- 8.0 > -4.00 -5.54 -5.68 
SK-OV-3 -5.7 -7.1 > -4.00 > -4.00 >-4.00 
Renal cancers      
786-0 -7.0 <- 8.0 a >- 4.00 >- 4.00 
A489 -5.9 <- 8.0 -7.03 -6.12 -7.08 
ACHN -7.5 <- 8.0 -6.58 -5.82 >-4.00 
CAKI-1 -7.5 <- 8.0 -7.53 -7.10 a 
RXF 393 -5.4 -7.6 -5.68 -5.83 -6.36 
SN12C -6.7 < -8.0 a > -4.00 a 
TK-10 -5.3 -7.8 -6.12 -4.74 a 
UO-31 -6.9 <-8.0 -6.40 a > -4.00 
Prostate cancers      
PC-3 -6.5 -7.5 -6.51 -4.62 -4.32 
DU-145 -6.6 <-.8.0 -6.02 -6.36 > -4.00 
Breast cancers      
MCF7 -8.2 <- 8.0 -> -4.00 -6.86 > -4.00 
NCI/ADR-RES -5.9 <- 8.0 > -4.00 -5.53 -5.01 
MDA-MB-231 -5.4 -7.4 > -4.00 -4.42 -6.56 
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HS 578T -5.4 -7.9 -4.80 -4.90 -5.82 
MDA-MB-435 -5.5 <- 8.0 -6.77 -6.60 -6.74 
MDA-N -5.9 -7.9 -6.76 - - 
BT-549 -6.0 -7.4 -5.23 -6.64 -6.26 
T-47D -5.9 < -8.0 a -4.75 a 
Mean graphs 
midpoint 
-6.4 -7.6 -5.56 -5.28 -5.39 
a) TGI values are not listed when the screening resulted in more than 100-fold 602 
different values. 603 
604 
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Figure 1 605 
Synthesis of the heterodinucleoside phosphate 2’-deoxy-5-fluorouridylyl-606 
(5’5’)-3’-C-ethynylcytidine (6) and 2’-deoxy-5-fluorouridylyl-(3’5’)-3’-C-607 
ethynylcytidine (7) according to the phosphonate method starting from 5’-O-(4-608 
monomethoxytrityl)-2’-deoxy-5-fluorouridine (1) and N4-benzoyl-2’-O-(tert-609 
butyldimethylsilyl)-3’-(trimethylsilylethynyl)cytidine (5). Reagents and 610 
conditions: (a) benzoylchloride, pyridine, (b) column chromatography on silica 611 
gel, (c) p-toluenesulfonic acid, acetone, (d) salicylchlorophosphite, 612 
pyridine/dioxane, (e) 1. pivaloylchloride,  pyridine, 2. iodine, 613 
THF/pyridine/water, (f) TBAF in THF, (g) satd. NH3/MeOH, (h) column 614 
chromatography on RP18. 615 
  616 
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